Overview

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Status:
Recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients. The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib
Gefitinib